Damaged-DNA Binding Protein-2 Drives Apoptosis Following DNA Damage by Srilata Bagchi & Pradip Raychaudhuri
REVIEW Open Access
Damaged-DNA Binding Protein-2 Drives
Apoptosis Following DNA Damage
Srilata Bagchi1, Pradip Raychaudhuri2*
Abstract
Apoptosis induced by DNA damage is an important mechanism of tumor suppression and it is significant also in
cancer chemotherapy. Mammalian cells activate the pathways of p53 to induce apoptosis of cells harboring irrepar-
able DNA damages. While p53 induces expression of various pro-apoptotic genes and directly participates in the
disruption of mitochondrial membrane polarization, it also increases expression of the cell cycle inhibitor p21 that
is a dominant inhibitor of caspase-activation and apoptosis. Here we discuss how Damaged-DNA Binding Protein-2
(DDB2) subdues the level of p21 in cells harboring irreparable DNA damage to support activation of the caspases.
We speculate a model in which DDB2 detects and couples the presence of un-repaired DNA damages to the pro-
teolysis of p21, leading to the induction of apoptosis.
Review
Cell cycle inhibitor p21 inhibits apoptosis following DNA
damage
The DNA damage response pathways are critical
mechanisms of tumor suppression, as these pathways
prevent accumulation of cells with oncogenic mutations.
Often the DNA repair pathways are insufficient to repair
all the damages. Under these circumstances permanent
arrest (premature senescence) or apoptosis is induced to
prevent accumulation of cells with oncogenic mutations.
It is unclear how cells sense the presence of irreparable
DNA damage - a situation when the extent of damage is
greater than repair-capacity of a cell. It is expected that
premature senescence or apoptosis would be induced
only after the cell has a window of opportunity to repair
the damages. A likely scenario is that a continued acti-
vation of the ATM/ATR beyond the attempts to repair
the damages is responsible for the induction of prema-
ture senescence or apoptosis. Apoptosis is clearly the
most effective tumor suppression mechanism following
DNA damage because it eliminates the cells harboring
irreparable DNA damages. The tumor suppressor p53 is
considered to be the central activator of the DNA
damage-induced apoptosis. Activated ATM/ATR cause
stabilization and activation of p53 (Reviewed in [1]).
Once activated, p53 directly and indirectly causes dis-
ruption of mitochondrial membrane polarization, lead-
ing to the activation of caspases - Apoptosis ensues.
Mechanisms of p53 involve transcriptional activation
of pro-apoptotic genes and inhibition of anti-apoptotic
genes. For example, p53 transcriptionally activates
expression of PUMA, BID, BAX, and NOXA (Reviewed
in [2]) to induce apoptosis. Also, the anti-apoptotic pro-
tein Survivin is inhibited by p53 [3]. In addition to these
mechanisms, p53 also translocates to mitochondria and
directly binds to Bcl-2 and inhibits its anti-apoptotic
activity. This latter phenomenon is termed transcrip-
tion-independent p53-induced apoptosis or TIPA [4].
While p53 activates the pro-apoptotic pathways, the
p53-induced cell cycle-inhibitory protein p21 was shown
also to be a potent inhibitor of apoptosis [5-8]. Expres-
sion of p21 is induced also by E2F1, which is another
pro-apoptotic gene [9,10]. In addition to stabilizing p53,
the ATM/ATR pathways stabilize E2F1, which induces
apoptosis through both p53 and p53-independent path-
ways [[10] and references therein].
The p53-mediated induction of p21 is partly responsi-
ble for the cell cycle delays observed after DNA damage
that is accomplished through inhibition of CDKs. The
CDK-inhibitory function of p21 is linked also to its anti-
apoptotic activity [6], and it has been suggested that the
execution of apoptosis requires CDK-activity [11]. How-
ever, the mechanisms by which CDKs participate in
apoptosis or p21 inhibits activation of the caspases are
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unclear. Nevertheless, the increase in p21 following
DNA damage is important, as it inhibits the apoptotic
pathway to allow a window of opportunity for cells to
repair the damaged-DNA. (However, a very high-level of
p21, as seen in the DDB2-/- cells, is inhibitory to repair
[[12] and references therein]) Thus, the increased
expression of p21 after DNA damage can be viewed as a
survival pathway. For cells to undergo apoptosis after
DNA damage, mechanisms must exist that reduce the
level of p21 to support activation of the caspases. Theo-
retically, a continued activation of ATM/ATR by the
un-repaired DNA damages will only increase the level of
p21 through stabilization of p53 and E2F1. On the other
hand, extinguishing the checkpoint pathways of ATM
and ATR is expected to lower the level of p21. Alterna-
tively, a pathway that overrides the p53-p21 inhibitory
loop without affecting the pro-apoptotic function of p53
might be significant in driving apoptosis following DNA
damage. The xeroderma pigmentosum group E (XP-E)
gene product DDB2 fits that bill nicely.
DDB2 is a substrate-adapter for the E3 ubiquitin ligase
Cul4-DDB1 [13]. In human cells, but not in rodent cells,
expression of DDB2 is induced by p53 [14]. Like p21,
expression of DDB2 in human cells also increases after
DNA damage [14]. Recent studies by Stoyanova et al.
[15] demonstrated that DDB2 targets p21 for ubiquitina-
tion and proteolysis in cells harboring DNA damage.
Under these conditions, DDB2 has no effect on the pro-
apoptotic pathway of p53 [15]. Below, we discuss how
DDB2 mediated proteolysis of p21 is important for cells
to undergo apoptosis following exposure to DNA dama-
ging agents.
Targeting p21 for proteolysis after DNA damage
P21 is targeted for proteasome-mediated proteolysis by
an impressive number of pathways: Both ubiquitin-
dependent and -independent pathways have been shown
to degrade p21. One study indicated that mutations of
all lysine-residues, which inhibited ubiquitination, had
no effect on the stability of p21 [16]. Also, the N-termi-
nus of p21 was found to be acetylated, suggesting that
p21 is degraded by a ubiquitin-independent mechanism.
It was shown that the ubiquitin-independent mechanism
involved the REGgamma complex [16,17]. Another
study indicated a role of Mdm2 in targeting p21 for pro-
teolysis by a ubiquitin-independent mechanism [18].
Other studies, on the other hand, demonstrated ubiqui-
tin-dependent proteolysis of p21. First, several reports
indicated an involvement of the SCF-SKP2 ligase for the
ubquitination and proteolysis of p21 in late G1 and in S
phases [19-22]. At G2/M phase, however, p21 was
shown to be poly-ubiquitinated by the APC/C-Cdc20
ligase complex [23]. In addition to the SCF and APC/C
ligases, the Cul4-DDB1 ligase has been shown to target
p21 for proteolysis. Interestingly, targeting by the Cul4-
DDB1 ligase involves PCNA and the substrate adapter
Cdt2 [24,25]. This pathway has been implicated in the
proteolysis of p21 also in the UV-irradiated cells. A
PCNA-binding mutant of p21 was not degraded after
UV irradiation. Also, a phosphomimetic substitution at
Ser114 of p21, a site that is phosphorylated by ATR
after UV irradiation [26], enhanced polyubiquitination
by the Cul4-DDB1-Cdt2 ligase [24]. On the other hand,
another study reported evidence for an unidentified ubi-
quitin-independent mechanism for the proteolysis of
p21 phosphorylated at Ser114 after UV irradiation [27].
Although many of these studies reported their results in
a controversial manner, it is obvious that the mamma-
lian cells have evolved to utilize multiple pathways to
insure efficient degradation of p21 in dividing cells to
allow unperturbed progression through the phases of
the cell cycle. Therefore, the inhibitory function of p21
is restricted to specific physiological context (such as
exposure to DNA damaging agents) in which the rate of
synthesis is greater than rate of degradation.
Studies on the DDB2-/- MEFs resulted in the identifi-
cation of yet another mechanism for ubiquitin-depen-
dent proteolysis of p21 [15]. Interestingly, DDB2-/-
MEFs exhibited only a marginal increase in the level of
p21. By contrast, following treatments with DNA dama-
ging agents, the DDB2-/- MEFs accumulated p21 at a
much higher level compared to the wild-type MEFs.
The high-level accumulation of p21 did not result from
a relatively greater increase in expression. Rather there
was a significant increase in the half-life of the p21 pro-
tein in the DDB2-/- MEFs. DDB2-deficient human cells
also exhibited a similar increase in the stability of p21
following treatment with DNA damaging agents. More-
over, the DDB2-deficient human cells exhibited a reduc-
tion in the polyubiquitination of p21 compared to the
DDB2-proficient cells, indicating that the DDB2-
mediated proteolysis of p21 following DNA damage
involves polyubiquitination of p21. DDB2 could bind
p21, and the binding ability was increased in cells har-
boring DNA damage [15]. These observations indicated
a significant role of DDB2 in the proteolysis of p21 fol-
lowing DNA damage.
The reduced polyubiquitination and proteolysis of p21
in the DDB2-deficient cells following DNA damage are
somewhat surprising given that p21 can be degraded by
multiple ubiquitin-dependent and -independent path-
ways. Nevertheless, the high-level accumulation of p21
suggests that the DDB2-mediated proteolysis of p21 is
critical following DNA damage. The DDB2-binding
partner DDB1 has been implicated in the proteolysis of
p21 [24,28]. Moreover, DDB2 in conjunction with DDB1
associates with Cul4 to form a functional E3 ligase.
Therefore, it is possible that a complex of Cul4, DDB1
and DDB2 is involved in the ubiquitination and
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proteolysis of p21 after DNA damage. On the other
hand, since the Cul4-DDB1-Cdt2 complex has been
implicated in the proteolysis of p21 after UV irradiation
[24,25], it is possible that DDB2 collaborates with that
complex to target p21 for proteolysis. The possibility
that DDB2 is required for multiple pathways of p21-pro-
teolysis could not be ruled out. For example, DDB2
increases nuclear level of DDB1 following UV irradiation
[12,29], causing an increase in the nuclear abundance of
the Cul4-DDB1 ligase. But, the interaction between
DDB2 and p21, and its increase following DNA damages
suggest a more direct role of DDB2 in targeting p21 for
ubiquitination. In that regard, it will be important to
consider the possibility that DDB2 plays a role in loca-
lizing p21 to the damaged-chromatin for proteolysis by
an available E3 ubiquitin ligase (such as the Cul4-
DDB1-Cdt2 complex).
DDB2-mediated proteolysis of p21 is a key activator of
apoptosis following DNA damage
Linn laboratory demonstrated that the DDB2 -/- MEFs
as well as XP-E cells are deficient in apoptosis following
UV irradiation [30,31]. These results were confirmed by
Stoyanova et al. [15]. Moreover, Stoyanova et al. further
demonstrated that the DDB2-deficienct cells are
impaired in apoptosis induced by ionizing radiation, cis-
platin and aclarubicin treatment. Furthermore, E2F1-
induced apoptosis also involved DDB2 [15]. The defi-
ciencies in apoptosis following DNA damage was
observed also in lymphocytes and in keratinocytes iso-
lated from the DDB2 -/- mice (unpublished observations
of Stoyanova and Raychaudhuri). The deficiency in
apoptosis did not result from a lack of expression of the
p53-induced pro-apoptotic genes. PUMA and BAX were
efficiently induced in the DDB2-/- MEFs following treat-
ments with the DNA damaging agents. Moreover, cell
fractionation studies indicated that the DNA damage-
induced localization of p53 to mitochondria was not
affected in the DDB2-deficient cells. However, the acti-
vation of caspase 3 and PARP cleavage were impaired,
suggesting that the DDB2-deficient cells are impaired in
caspase activation following disruption of mitochondrial
membrane polarization.
CDK-inhibitors were shown to strongly inhibit ioniz-
ing radiation-induced caspase processing and activation
without affecting the mitochondrial events [6]. It has
been suggested that the activation of caspases requires
CDK-activity. Interestingly, in the DDB2-/- MEFs, the
lack of DNA damage-induced apoptosis coincided with
the high-level accumulation of p21 [15]. Moreover,
those cells exhibited a greatly reduced CDK-activity. To
determine whether the accumulation of p21 was respon-
sible for the blockade of apoptosis in the DDB2-defi-
ciencient cells, Stoyanova et al. deleted p21 in the
DDB2-/- background. The DDB2-/-p21-/- MEFs did not
exhibit any deficiency in apoptosis following DNA
damage. Moreover, the E2F1-induced apoptosis also was
restored in the DDB2-/-p21-/- MEFs. Together those
observations clearly demonstrated that the lack of pro-
teolysis of p21 and consequent accumulation of p21 in
the DDB2-deficient cells is responsible for the inhibition
of apoptosis following DNA damage.
A recent study indicated that Mdm2, along with p21, is
required for efficient inhibition of CDK2 in cells treated
with DNA damaging agents [32]. SiRNA-mediated deple-
tion of Mdm2 leads to inefficient arrest by the DNA
damaging agents. In agrement with that, Stoyanova et al.
Table 1 Reduced expression of DDB2 in cancer (Source: Oncomine)
DDB2 among top 5-10% under-expressed genes
(Oncomine - Expression Signature): Cancer types
Database References
Brain and CNS cancer Sun Brain Cancer Cell (2006), 9: 287-300
Colon Adenocarcinoma Kaiser Colon Genome Biol (2007) 8: R131
Ductal breast carcinoma Richradson breast 2 Cancer Cell (2006) 9: 121-132
Ductal breast carcinoma Huang Breast Lancet (2003) 361: 1590-1596
Follicular Lymphoma Storz J. Invest Dermatol. (2003) 120: 865-870
T-cell Prolymph.leukemia Durig leukemia Leukemia (2007) 10: 2153-2163
Chronic Lymph. leukemia Rosenwald leukemia N Engl J Med (2002) 346: 1937-1947
Burkitt’s lymphoma Basso lymphoma Nat. Genet. (2005) 37: 382-390
Liver cancer (HCC) Warmbach Liver Hepatology (2007) 45: 938-947
Liver cancer (HCC) Chen Liver Mol. Biol. Cell. (2002) 13: 1929-1939
FAB subtype M2 Wouter’s leukemia Blood (2009) 113: 3088-3091
Head and Neck SCC Chung SCC Cancer Cell (2004) 5: 489-500
Lung adenocarcinoma Beer Lung Nat. Med. (2002) 8:816-824
Ovarian adenocarcinoma Welsh Ovary PNAS (2001) 98: 1176-1181
Prostate adenocarcinoma Vanaja Prostate Cancer Res. (2003) 63: 3877-3882.
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showed that depletion of Mdm2 in the DDB2-deficient
cells increased CDK2-activity, which was retained to a sig-
nificant extent after treatment with DNA damaging agents
[15]. Moreover, depletion of Mdm2 in the DDB2-deficient
cells also restored apoptosis induced by DNA damaging
agents [15]. These observations further support the notion
that DDB2 activates CDK2 by inducing proteolysis of p21
to then allow cells to activate the caspases and undergo
apoptosis following DNA damage.
Why DDB2?
DDB2 is unique among the other E3 ligase-associated
proteins that have been implicated in the proteolysis of
p21 in that it has a very high affinity for damaged-DNA.
It binds to UV-damaged DNA, cisplatin-modified DNA,
as well as single-stranded DNA with high affinities [33].
It binds damaged-DNA in conjunction with DDB1 [[33]
and references therein]. Moreover, the DDB2-DDB1
complex can also recruit Cul4 to the damaged-DNA
[12,34]. The damaged-DNA binding activity of DDB2
has been implicated in its nucleotide excision repair
(NER) function. It was shown that Cul4-DDB1-DDB2
complex could ubiqutinate histones [35,36]. Based on
that observation, it was suggested that DDB2 partici-
pates in NER by modifying chromatin structure at the
site of UV-damage. While the model is intriguing, a
clear evidence for DDB2-mediated histone-ubiquitina-
tion in NER is still lacking. We found the repair-defi-
ciencies of the DDB2-/- MEFs could be reversed by the
deletion of p21 [12]. We proposed that DDB2 partici-
pates in NER indirectly by regulating the levels of p21.
However, it remains possible that two mechanisms are
linked: Histone-ubiquitination might be involved in the
proteolysis of p21 on the damaged-chromatin.
The damaged-DNA binding activity of DDB2 might be
related also to its apoptotic activity. For example, we
speculate that, in addition to a potential role in repair,
the damaged-DNA binding activity of DDB2 might be
significant in sensing the un-repaired DNA damages
when the extent of damage is greater than repair-cap-
ability of a cell. After sensing the un-repaired DNA,
DDB2 channels cells to proceed through the apoptotic
pathway by inducing proteolysis of the apoptosis-regula-
tor p21. The Cul4-DDB1-Cdt2 complex was shown to
induce proteolysis of Cdt1 in the context of chromatin
[37]. It is possible that a similar mechanism involving
damaged-chromatin is required for the proteolysis of
p21 by DDB2 - Such a mechanism would couple the
presence of un-repaired damaged-chromatin to the pro-
teolysis of p21, thereby allowing apoptosis to proceed
when it is important.
Conclusion
DNA damage-induced apoptosis is significant not only
as a mechanism of tumor suppression it is also a
mechanism that is used by the chemotherapy drugs to
eliminate cancer cells. Many of the chemotherapy drugs
are also DNA-damaging agents, and they function by
inducing apoptosis. Stoyanova et al. demonstrated that
both normal and cancer cells lacking DDB2 are resistant
to apoptosis induced by the chemotherapy drugs cispla-
tin and aclarubicin [15]. Thus, DDB2 is important for
the therapeutic efficacies of the drugs. In support of that
notion, a recent reported that expression of DDB2 sensi-
tizes cancer cells to therapy [38]. A corollary to these
observations is that reduced expression of DDB2 would
lead to drug resistance of cancer cells. In that regard, it
is noteworthy that DDB2 is a p53-induced gene, and
p53 is mutated in greater than 50% of cancers. Consis-
tent with that, a search of the Oncomine database
revealed that DDB2 is one of the top 10% under-
expressed genes in a variety of cancers (Table 1). It will
be important to analyze the mechanisms, other than
p53, that stimulate expression of DDB2 because the
information can be used to increase expression of DDB2
in tumors and sensitize them to chemotherapeutic
drugs.
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